Stonehage Fleming Financial Services’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Stonehage Fleming Financial Services’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-350	Closed	-$35K	–	242
2021 Q3	$35K	Hold	350	–	–	﹤0.01%	195
2021 Q2	$50K	Buy	+350	New	+$39.5K	﹤0.01%	172

Other funds holding RETA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Stonehage Fleming Financial Services's RETA Position: Q4 2021 in Review

Stonehage Fleming Financial Services sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q4 2021, closing a stake of 350 shares — an estimated $35K sold.

Stonehage Fleming Financial Services first reported a position in RETA in Q2 2021 and held it in 2 quarters. The position peaked at $50K in Q2 2021. 151 funds tracked by Wall St. Rank hold RETA as of Q4 2021.

Stonehage Fleming Financial Services reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q4 2021 after selling out during the quarter.
Stonehage Fleming Financial Services sold 350 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q4 2021, an estimated $35K.
Stonehage Fleming Financial Services first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2021 and held it in 2 quarters.
Stonehage Fleming Financial Services's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $50K in Q2 2021.
151 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q4 2021.

Based on Stonehage Fleming Financial Services's 13F filing for Q4 2021, filed 2 Feb 2022.